The Centers for Medicare & Medicaid Services' Form 2746, the Death Notification Form, was revised in 2004. In addition to questions inquiring about discontinuation of dialysis, the revised form includes questions about patient and family involvement in the decision to discontinue treatment, whether the patient had received hospice care, as well as a new Cause of Death item #104, "Withdrawal from dialysis/uremia" However Form 2746 offers no instructions or explanation on how to decide whether a death is attributable to withdrawal from dialysis/uremia or what is considered dialysis discontinuation. We conducted a standardized telephone survey (N = 338) among front-line dialysis facility professionals (staff nurses, social workers, nurse managers) in ESRD Networks 1, 5, and 12, inquiring about 448 deaths of patients who discontinued dialysis. Only 70% of front-line staff reported Form 2746 was clear on when to indicate dialysis discontinuation, and only 57% reported it was clear when to use the death code #104 for withdrawal/uremia. According to facility staff, 49% of patients in the study group actively participated in the decision to discontinue dialysis. However only 8% of staff were aware of the patient's decision to discontinue dialysis by actually participating in the decision. Front-line staff knew that 43% of patients in the study discussed end of life issues prospectively, but only 57% of patients involved in discussions about dialysis discontinuation had interaction with physicians, according to the staff. We also found regional variations in dialysis discontinuation between the three Networks that participated in the study. This data indicates a lack of discussions about end of life issues with patients, even when they do occur, and sparse communication about the occurrence of these discussions with front-line staff. The study committee consisting of experienced nephrologists in kidney disease care and experts in end of life/palliative care who provided definitions for discontinuation and withdrawal from dialysis. Dialysis facilities should identify patients that have a greater probability of discontinuation. Front-line dialysis facility staff such as nurses and social workers should be aware of end of life discussions of their patients. Dialysis facilities should also have a process in place for end of life discussions that involves the interdisciplinary team, as suggested in the recently revised Conditions for Coverage for Participation for dialysis facilities.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dialysis discontinuation
16
dialysis
15
front-line dialysis
12
dialysis facility
12
facility staff
12
form 2746
12
decision discontinue
12
front-line staff
12
dialysis facilities
12
staff
9

Similar Publications

Fumagillin Shortage: How to Treat Microsporidiosis in Solid Organ Transplant Recipients in 2024?

Transpl Int

December 2024

Service de Parasitologie-Mycologie, 3IHP, Inserm U1071, M2iSH, USC-INRAE 1382, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Unlabelled: Intestinal microsporidiosis caused by is an opportunistic infection that especially affects solid organ transplant (SOT) recipients. Management revolves around tapering the immunosuppressive regimen and/or using a specific anti-microsporidia treatment, but only fumagillin has demonstrated efficacy for treatment of this infection. Since fumagillin has been commercially discontinued, nitazoxanide is increasingly being used in this indication.

View Article and Find Full Text PDF

Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease.

J Pharm Technol

December 2024

Division of Outcomes and Practice Advancement, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

Expansion of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) prompted a pragmatic study of their safety and effectiveness in patients with type 2 diabetes mellitus (T2DM) and late-stage CKD. The primary clinical endpoint was change in HbA. Secondary clinical endpoints included change in body weight and blood pressure.

View Article and Find Full Text PDF

Objective: This study compared the outcomes of two cohorts of patients with coronavirus disease 2019 (COVID-19) who received COVID-19 convalescent plasma transfusions between 2020 and 2021.

Methods: This retrospective study was conducted at a tertiary hospital in São Paulo, Brazil. We included a retrospective cohort of patients who received convalescent compassionate plasma, and another group of patients from a previous clinical study.

View Article and Find Full Text PDF

Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder with heterogeneous presentation, where acute encephalopathy is rarely described in literature. Therefore, initial neurologic symptoms could make the diagnosis and treatment challenging.

Case Presentation: A four-month-old male infant presented with acute encephalopathy, vomiting, bulging fontanel, decreased appetite and failure to thrive.

View Article and Find Full Text PDF

Central hypothyroidism caused by roxadustat.

Tidsskr Nor Laegeforen

December 2024

Nyremedisinsk seksjon, Medisinsk klinikk, Sykehuset i Vestfold, Tønsberg.

Background: Isolated central hypothyroidism, although rare, has been documented in case reports in patients with chronic kidney disease (CKD) treated with roxadustat, a novel agent in the treatment of renal anaemia.

Case Presentation: A woman in her sixties with CKD stage 5 (not in dialysis) and no prior thyroid disease, was started on treatment with roxadustat 70 mg x 3 weekly for renal anaemia. During treatment, the patient developed classic signs of hypothyroidism (fatigue, dry skin, constipation, difficulty concentrating), with blood samples consistent with isolated central hypothyroidism.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!